Johnson & Johnson (JNJ) Non-Current Assets (2009 - 2026)
Johnson & Johnson (JNJ) posted Non-Current Assets of $141.7 billion for Q1 2026, down 1.3% sequentially from $143.6 billion in Q4 2025, and up 16.05% YoY from $122.1 billion in Q1 2025.
Johnson & Johnson (JNJ) Non-Current Assets (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Non-Current Assets data on file, last reported at $141.7 billion in Q1 2026.
- Quarterly Non-Current Assets rose 16.05% year-over-year to $141.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $562.4 billion (up 13.7% YoY) and the FY2025 annual result came in at $143.6 billion, up 15.6% from the prior year.
- Non-Current Assets retreated to $141.7 billion in Q1 2026 per JNJ's latest filing, from $143.6 billion in the prior quarter.
- The five-year high for Non-Current Assets was $143.6 billion in Q4 2025, with the low at $109.9 billion in Q4 2022.
- Average Non-Current Assets over 5 years is $125.3 billion, with a median of $123.7 billion recorded in 2024.
- Year-over-year, Non-Current Assets decreased 13.64% in 2023 and advanced 16.05% in 2026.
- Johnson & Johnson's Non-Current Assets stood at $109.9 billion in 2022, then advanced by 3.8% to $114.1 billion in 2023, then gained by 8.9% to $124.2 billion in 2024, then increased by 15.6% to $143.6 billion in 2025, then slipped by 1.3% to $141.7 billion in 2026.
- Business Quant data shows JNJ's Non-Current Assets at $141.7 billion in Q1 2026, $143.6 billion in Q4 2025, and $138.2 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 61.74 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 141.72 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 102.93 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 84.40 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 125.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 61.03 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 37.64 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 165.18 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 20.29 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 141.72 Bn |
| Dec 28, 2025 | 143.59 Bn |
| Sep 28, 2025 | 138.21 Bn |
| Jun 29, 2025 | 138.89 Bn |
| Mar 30, 2025 | 122.12 Bn |
| Dec 29, 2024 | 124.21 Bn |
| Sep 29, 2024 | 125.04 Bn |
| Jun 30, 2024 | 123.27 Bn |
| Mar 31, 2024 | 114.96 Bn |
| Dec 31, 2023 | 114.06 Bn |
| Oct 1, 2023 | 112.36 Bn |
| Jul 2, 2023 | 131.12 Bn |
| Apr 2, 2023 | 131.58 Bn |
| Jan 1, 2023 | 132.08 Bn |
| Oct 2, 2022 | 109.89 Bn |
| Jul 3, 2022 | 113.88 Bn |
| Apr 3, 2022 | 117.93 Bn |
| Jan 2, 2022 | 121.04 Bn |
| Oct 3, 2021 | 119.34 Bn |
| Jul 4, 2021 | 122.67 Bn |